Updated interim data from a Phase 1 clinical trial continues to support the safety and anti-tumor activity of Sutro Biopharma’s STRO-002 for heavily pre-treated women with advanced ovarian cancer. About one-quarter of patients receiving a dose of 2.9 mg/kg or higher responded to this investigational antibody-drug conjugate, and nearly half (44%) had responses lasting at least 16 weeks, results showed. These findings were presented by Wendel Naumann, MD, the trial’s principal investigator, in a virtual poster, “Phase 1 Dose-Escalation Study…
You must be logged in to read/download the full post.
The post STRO-002 Trial Update Supports Its Safety, Activity in Advanced Cancer appeared first on BioNewsFeeds.